Changes in immune cell populations following KappaMab, lenalidomide and low‐dose dexamethasone treatment in multiple myeloma

OBJECTIVES: Lenalidomide (LEN) is used to treat multiple myeloma (MM) and shows in vitro synergy with KappaMab (KM), a chimeric antibody specific for Kappa Myeloma antigen, an antigen exclusively expressed on the surface of kappa‐restricted MM cells. Lenalidomide, dexamethasone (DEX) and KM control...

Descripción completa

Detalles Bibliográficos
Autores principales: Norton, Samuel E, Khong, Tiffany, Ramachandran, Malarmathy, Highton, Andrew J, Ward‐Hartstonge, Kirsten A, Shortt, Jake, Spencer, Andrew, Kemp, Roslyn A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688504/
https://www.ncbi.nlm.nih.gov/pubmed/38034081
http://dx.doi.org/10.1002/cti2.1478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688504/
https://www.ncbi.nlm.nih.gov/pubmed/38034081
http://dx.doi.org/10.1002/cti2.1478

Ejemplares similares